A rapid, PPAR-γ-dependent effect of pioglitazone on the phosphorylation of MYPT

American Journal of Physiology - Cell Physiology

Volumn 296, Issue 5, 2009, Pages

  Atkins, Kevin B ^a,b   Irey, Brittany ^a   Xiang, Nan ^a   Brosius III, Frank C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Myosin phosphatase regulatory subunit; Peroxisome proliferator activated receptor ; Vascular

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; MYOSIN; MYOSIN PHOSPHATASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LYSATE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME PHOSPHORYLATION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

AMIDES; ANILIDES; ANIMALS; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; MUSCLE, SMOOTH, VASCULAR; MYOSIN-LIGHT-CHAIN KINASE; PHOSPHORYLATION; PPAR GAMMA; PROTEIN PHOSPHATASE 1; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; THREONINE;

RATTUS;

EID: 66149140549     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00343.2008     Document Type: Article

References (28)

1. Ali SS, Igwe RC, Walsh MF, Sowers JR. Troglitazone and vascular reactivity: role of glucose and calcium. Metabolism 48: 125-130, 1999.
2. Atkins KB, Northcott CA, Watts SW, Brosius FC. Effects of PPAR-γ ligands on vascular smooth muscle marker expression in hypertensive and normal arteries. Am J Physiol Heart Circ Physiol 288: H235-H243, 2005.
3. Boonyaratanakornkit V, Edwards DP. Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med 25: 139-153, 2007.
4. 2+ sensitization of contraction in arterial smooth muscle. Circ Res 100: 121-129, 2007.
5. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70: 177-188, 2005.
6. Goud C, Pitt B, Webb RC, Richey JM. Synergistic actions of insulin and troglitazone on contractility in endothelium-denuded rat aortic rings. Am J Physiol Endocrinol Metab 275: E882-E887, 1998.
7. Hartshorne DJ, Ito M, Erdödi F. Role of protein phosphatase type 1 in contractile functions: myosin phosphatase. J Biol Chem 279: 37211-37214, 2004.
8. 2+ sensitization of the contractile apparatus in vascular smooth muscle. J Pharm Sci 104: 109-115, 2007.
9. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21: 1891-1895, 2001.
10. Je HD, Park SY, Barber AL, Sohn UD. The inhibitory effect of rosiglitazone on agonist-induced or spontaneous regulation of contractility. Arch Pharm Res 30: 461-468, 2007.
11. 2+ sensitization in rabbit smooth muscle. J Physiol 546: 879-889, 2003.
12. Li Z, Ajdic J, Eigenthaler M, Du X. A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. Blood 101: 4423-4429, 2003.
13. Lincoln TM. Myosin phosphatase regulatory pathways: different functions or redundant functions? Circ Res 100: 10-12, 2007.
14. Little PJ, Osman N, de Dios ST, Cemerlang N, Ballinger M, Nigro J. Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. Cardiovasc Diabetol 6: 33, 2007.
15. Newaz M, Yousefipour Z, Oyekan A. Role of PPAR-gamma on the pathogenesis and vascular changes in glycerol-induced acute renal failure. Pharmacol Res 54: 234-240, 2006.
16. Ruiz E, Redondo S, Gordillo-Moscoso A, Tejerina T. Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway. J Pharmacol Exp Ther 321: 431-438, 2007.
17. Scatena R, Bottoni P, Martorana GE, Vincenzoni F, Botta G, Pastore P, Giardina B. Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. Eur J Pharmacol 567: 50-58, 2007.
18. Schindler C, Ferrario CM, Jatzke C, Ahner K, Brosnihan KB, Bramlage P, Maywald U, Oertel R, Boecking W, Kirch W. Characterization of vascular reactivity in dorsal hand veins after oral rosiglitazone treatment in healthy subjects. Int J Clin Pharmacol Ther 46: 30-39, 2008.
19. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 372: 231-236, 1994.
20. Swärd K, Mita M, Wilson DP, Deng JT, Susnjar M, Walsh MP. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep 5: 66-72, 2003.
21. Trovati M, Massucco P, Mattiello L, Costamagna C, Aldieri E, Cavalot F, Anfossi G, Bosia A, Ghigo D. Human vascular smooth muscle cells express a constitutive nitric oxide synthase that insulin rapidly activates, thus increasing guanosine 3′:5′ -cyclic monophosphate and adenosine 3′:5′-cyclic monophosphate concentrations. Diabetologia 2: 831-8399, 1999.
22. Verma S, Bhanot S, Arikawa E, Yao L, McNeill JH. Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 56: 7-16, 1998.
23. Wakino S, Hayashi K, Kanda T, Tatematsu S, Homma K, Yoshioka K, Takamatsu I, Saruta T. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res 95: e45-e55, 2004.
24. Watterson KR, Ratz PH, Spiegel S. The role of sphingosine-1-phosphate in smooth muscle contraction. Cell Signal 17: 289-298, 2005.
25. Webb RC. Smooth muscle contraction and relaxation. Adv Physiol Educ 27: 201-206, 2003.
26. Ca channel activity in coronary artery smooth muscle cells. Circ Res 86: 897-905, 2000.
27. 2+ sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem J 389: 763-774, 2005.
28. Wooldridge AA, MacDonald JA, Erdodi F, Ma C, Borman MA, Hartshorne DJ, Haystead TA. Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of serine 695 in response to cyclic nucleotides. J Biol Chem 279: 34496-34504, 2004.